Abstract
Objective
To investigate the cost-effectiveness of a widespread prenatal population-based fragile X carrier screening program.Study design
A decision tree was designed comparing screening versus not screening for the fragile X mental retardation protein 1 premutation in all pregnant women. Baseline values included a prevalence of fragile X mental retardation protein 1 premutations of 3.3 per 1000, a premutation expansion rate of 11.3%, and a 99% sensitivity of the screening test. The cost of the screening test was varied from 75 US dollars to 300 US dollars. A sensitivity analysis of the probabilities, utilities, and costs was performed.Results
The screening strategy would lead to the identification of 80% of the fetuses affected by fragile X annually. Assuming the cost of 95 US dollars per test and only one child, the program would be cost effective at 14,858 US dollars per quality-adjusted life-year. The screening strategy remained cost effective up to 140 US dollars per test and 1 child per woman or for 2 children per woman up to a cost of 281 US dollars per test.Conclusion
Population-based screening for the fragile X premutation may be both clinically desirable and cost effective. Prospective pilot studies of this screening modality are needed in the prenatal setting.References
Articles referenced by this article (36)
An assessment of screening strategies for fragile X syndrome in the UK.
Health Technol Assess, (7):1-95 2001
MED: 11262423
Cognitive functioning and information processing of adult mentally retarded men with fragile-X syndrome.
Am J Med Genet, (2):190-200 1994
MED: 8010351
Title not supplied
2002
Relationship of deficits of FMR1 gene specific protein with physical phenotype of fragile X males and females in pedigrees: a new perspective.
Am J Med Genet A, (2):127-134 2003
MED: 12655493
Fragile X syndrome and deletions in FMR1: new case and review of the literature.
Am J Med Genet, (4):430-434 1997
MED: 9375726
American College of Medical Genetics
Am J Med Genet 1994
Technical standards and guidelines for fragile X: the first of a series of disease-specific supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics. Quality Assurance Subcommittee of the Laboratory Practice Committee.
Genet Med, (3):200-205 2001
MED: 11388762
Fragile-X carrier screening and the prevalence of premutation and full-mutation carriers in Israel.
Am J Hum Genet, (2):351-360 2001
MED: 11443541
Show 10 more references (10 of 36)
Citations & impact
Impact metrics
Citations of article over time
Alternative metrics
Discover the attention surrounding your research
https://www.altmetric.com/details/170613739
Article citations
Research needs for birth defect prevention and control in China in the genomic screening era.
BMJ, 386:e078637, 30 Aug 2024
Cited by: 0 articles | PMID: 39214555 | PMCID: PMC11359722
Benefits and harms of antenatal and newborn screening programmes in health economic assessments: the VALENTIA systematic review and qualitative investigation.
Health Technol Assess, 28(25):1-180, 01 Jun 2024
Cited by: 1 article | PMID: 38938110
ReviewBooks & documents Free full text in Europe PMC
Attitudes of medical professionals toward fragile X carrier screening and genetic counseling in China.
J Community Genet, 15(2):177-185, 26 Jan 2024
Cited by: 0 articles | PMID: 38277068 | PMCID: PMC11031535
Carrier Screening Programs for Cystic Fibrosis, Fragile X Syndrome, Hemoglobinopathies and Thalassemia, and Spinal Muscular Atrophy: A Health Technology Assessment.
Ont Health Technol Assess Ser, 23(4):1-398, 10 Aug 2023
Cited by: 2 articles | PMID: 37637488 | PMCID: PMC10453298
Review Free full text in Europe PMC
Fragile X Syndrome Secondary to in Vitro Fertilization With a Family Egg Donor: A Case Report and Review of the Literature.
J Family Reprod Health, 15(2):130-135, 01 Jun 2021
Cited by: 1 article | PMID: 34721603 | PMCID: PMC8520665
Go to all (53) article citations
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Economic evaluation of prenatal carrier screening for fragile X syndrome.
J Matern Fetal Med, 8(4):168-172, 01 Jul 1999
Cited by: 8 articles | PMID: 10406300
Economic evaluation of prenatal population screening for fragile X syndrome.
Community Genet, 8(2):68-72, 01 Jan 2005
Cited by: 9 articles | PMID: 15925881
The cost-effectiveness of prenatal screening for spinal muscular atrophy.
Am J Obstet Gynecol, 202(3):253.e1-7, 01 Mar 2010
Cited by: 28 articles | PMID: 20207244
Screening for fragile X syndrome.
Health Technol Assess, 1(4):i-iv, 1-71, 01 Jan 1997
Cited by: 10 articles | PMID: 9414543
Review